Merck Serono’s Phase III CLARITY trial of its oral formulation of cladribine met the two-year primary endpoint of clinical relapse rate reduction in patients with relapsing-remitting multiple sclerosis (MS).       The two cladribine tablet treatment groups of the study, assessing different doses, demonstrated a statistically significant reduction in the annualized rate of relapses compared to placebo. Patients from the lower total dose group experienced a 58% relative reduction compared...